<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 298 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page297.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=298">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 298 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 298</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=298"><img src="../thumb/298.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Anti-Microbials - 18.12                                                        2020-04 / 261
       Side effects: Skin rash, GI disturbs., revers. neurolog. reacts./dizzin./  ADCO-ACYCLOVIR, (Adco Generics)    Drug interactions: Plasma conc.of other compds. that are CYP3A4
       somnol.esp.in ren. impairm., haematolog.chang., fatig., headache,   AI Pharm Ltd.[P/S]  substrat.poss.decr., AUC & C max of indinavir/saquinavir/rifampicin &
       accelerat.diffuse hair loss.  Acyclovir.                   clarithromycin decr., incr.freq.of S/E with ritonavir, methadone plas-
       Special precautions: Concom.nephrotox.meds. incr.risk of ren.  Indications: (S1) H.simplex viral infects.of lips.  ma lev.decr.result.in opiate withdr.signs in HIV infect.IV drug users,
       impairm., adeq.hydrat.in elderly, ren.impairm.  Indications: (S4) H.simplex type 1 & 2 viral infects. of skin & geni-  expect.reduc.conc.with St John’s Wort
       Drug interactions: Probenecid incr.plasma half-life.  talia in init.& recurr.situat.  ADCO EMTEVIR, AI Pharm Ltd [P/S] &
       ACYRAX, Pharma Dynamics [P/S]  CREAM, [P/S] 28/20.2.8/0369.  Emtricitabine 200 mg, tenofovir disoproxil fumarate 300 mg
                                     824674-006: 0,05 g/g, 2 g, R25,10
       Acyclovir                     824674-014: 0,05 g/g, 10 g, R125,52  Indications: In combinat.with other antiretrovir.in adults with HIV-1
       Indications: Treatm.& prophylax.of H. simplex infects.in immuno-  Dosage: Adults & childr: Beg.treatm.as soon as poss. Apply 5-6x/  infect., pre-expos.prophylax. (PrEP) in combinat.with safer sex practic.
       comprom.pts., treatm.of Varicella-Zoster infects.in immunocomprom.  day at 3-4 hr.interv. x5-10 days.  in adults prov. HIV-1 seroneg.to reduc.risk of sexual.acquir. HIV-1 in
       pts.(in shingles only if lesions not older than 72 hrs.& use in chick-  Contraindications: Safety in pregn.& lactat.not est.  pts.at high risk provid.max.compliance adher.to & monit.
       enpox may prev.pneumon.complicat.), H.simplex infects.in neonate,   Side effects: Trans.burn./sting., erythem., mild dryn.& skin flak.  (S4) TABS, 44/20.2.8/0835
       H.simplex encephalit., prevent.of reactivat.of cytomegalovirus infect.  (S4) TABS, [P/S] 28/20.2.8/0552.  715997-002: 30, R244,97
       in sero-positiv.pts.aft.bone marrow transplantat.  Indications: Init.& recurr.H.simplex.infects.of skin & mu-  Dosage: 1 tab.once dly.without regard to food.
       (S4) SOL FOR IV INFUS, A48/20.2.8/0387  cous membr., init.& recurr.genit.H.simplex., suppress. of recurr.  Contraindications: Safety & effic.not est.in hepatit. B vir.& HIV co-
       722095-001, 250 mg/10 ml, 5x10 ml vials, R507,00  genit.H.simplex in immuno-compet.pts., prophylax.of H.simplex.  infects., chron.HBV infect. treatm., safety in pregn.& lactat.not est.,
       Dosage: Admin.only by slow IV infus.over 1 hr. Do not admin.as   mod.to sev.ren.impairm., creatin.clear. &lt; 60 ml/min when used for
       IV bolus inj. Durat.of treatm norm 5 days accord.to pts.condit.&   infects.in immunocomprom.pts., treatm.of H.zoster infects.if le-  PrEP & &lt; 50 ml/min when used for treatm. of HIV-1., safety & effic.
                                     sions not older than 72 hrs., treatm.of Varicella-Zoster within 24
       respons. Durat.of treatm. for H.encephalit.& neonat.H.simplex in-  in paed.pts.less than 18 yrs. not est., concom.drugs contain tenofovir/
       fects: Usual.10 days. Calc.dos on ideal BM in obese pts.to avoid OD.  hrs.of typic.chickenpox rash.  emtricitabine or lamivudine, PrEP in indiv.not fully committ.to treatm.
                                     827282-001: 200 mg, 25, R79,24
       H.simplex infect: Immunocomprom: Adults: 5 mg/kg 8 hrly.   compl./indiv.with unknown/ posit. HIV-1 status., not to be used as
       Childr.3 mnths-12 yrs: 250 mg/m  8 hrly  Dosage: Adults: Init.& recurr.skin & mucous membr.H.simplex.   part of triple nucleoside regim., rare heredit probl., galact.intol. hist.,
                      2
                                     infects: 200 mg 5x/day 4  hrly. omitt.night time dos.x5 days. In sev.
       Neonates: H.simplex infects: 10 mg/kg 8 hrly.              Lapp lact.defic., gluc.-galact.malabsorpt.
       Varicella-zoster: Immunocomprom.(norm. ren. funct): Adults:   immunocompromis. pts./pts. with imp.gut absorpt. dos.may be doubl.  Side effects: Lactic.acidos.& sev.hepatomegaly with steatos.incl.
                                     to 400 mg or alternat.IV therapy.
       10 mg/kg 8 hrly. Childr. 3 mnths -12 yrs: 500 mg/m  8 hrly.  fatal.esp.in women, ac.ren.fail.& Fanconi syndr., sev.ac.exacerbat.
                             2
       H.simplex encephalit: Norm./ immunocomprom: (norm.ren.  Suppress.of recurr.genit.H.simplex infects. in immunocompe-  of hepatit.B aft. discontin., neutropen., anaem., GI disturbs., rais.
       funct): Adults: 10 mg/kg 8 hrly. Childr. 3 mnths-12 yrs: Norm.with   tent.adults: 200 mg 4xdly, 6 hrly/400 mg 2xdly 12 hrly. Titrat.down to   liv. enzym., asthen., pain, hyperbilirubinaem., hypertriglyceridaem.,
       norm.ren. funct: 500 mg/m  8 hrly.  200 mg 8-12 hrly may prove effect. Interrupt at 6 -12 mnthly. interv.to   hyperglycaem., arthralg., myalg., dizzin., insomn., abnorm.dreams/
                  2
       CMV reactivat.prev.follow.bone marrow transplantat: Adults   observe any poss.changes.  behav., hyperton.,convuls.,  neuropathy, periph.neurit., paraesthes.,
                    2
       & childr.over 2 yrs: 500 mg/m  IV 3xdly.(approx. 8 hrly).begin. 5 days   H.simplex prophylax in immunocomprom. adults: 200 mg   depress., incr.cough, rhinit., allerg./ skin reacts., hyperpigmentat.
       bef.op up to 30 days aft.transplant.  4xdly 6 hrly. In sev.compromis. pts./pts.with imp.gut absorpt.dos.  on palms &/soles, haematur., pancreatit., hepatit., hepatotox.,
       Contraindications: Valaciclov.hypersens., safety in pregn.not est.  may be doubl.to 400 mg.or IV therapy consid., durat.of therapy de-  hypophosphataem./-kalaemia, body fat redistribut./ accumulat.incl.
       Side effects: Freq: Phlebit., N&V, revers.liv.relat. enzym. incr.,   termin.by period at risk.  Cushingoid appear., fac. & periph.wast., breast enlargem., hypercho-
       prurit.,urticar., rashes incl.photosens., incr. bld.urea/creatin. Less   Varicella-Zoster infects.in adolescents (12 -18 yrs): 800 mg   lesterolaem., back pain, headache, proxim. tubulopathy, ren.insuff./
       freq: Anaem., thrombocytopen., leukopen., anaphylax., angioed., agi-  dly x5 days.  fail., ac.tubul. necros., nephrit., nephrogen. diab.insipid., polyur.,
       tat., confus., hallucinat., psychot.sympts., somnol., headache, dizzin.,   H.zoster & Varicella-Zoster infects.in adults: 800 mg 5xdly at   dyspn., bone dens.reduct., osteonecros./-malacia/ -penia, immune
       trem., atax., dysarthr., convuls., encephalopathy, coma, dyspn., diarrh.,   approx. 4 hrly interv., omit night-time dos.x7 days. Sev.immunocom-  reconstit.inflammat.syndr., creatin. kinase elevat., myopathy, rhab-
       abdom. pain, revers.incr.bilirub., jaund., hepatit, ren. impairm./fail./  prom.or pts. with imp.gut absorpt: IV dos.to be consid.  domyolys., musc. weakn.
       pain, fatig., fev., loc.inflamm. reacts.somet.lead.to skin breakdown   Contraindications: Safety in pregn.& lactat.not est.  Warnings and special precautions: Cont.lact., opportunist.
       with inadvert. extracellul.tiss.infus. Freq.unknown: Eryth. multiform.,   Side effects: GI disturbs., headache, skin rash, revers.neurologic.  infects.& HIV complicat.may contin., PrEP only as part of compre-
       Stev.-Johns.syndr., tox.epiderm. necrolys.  reacts., fatig.  hens.prevent. strategy that incl.other.prevent.meas., prev.of risk of
       Warnings and special precautions: Ensure adeq.hydrat. as   Special precautions: Ren.impairm., adeq. hydrat., pass.in breast   HIV transmiss. not proven, obesity & prolong. nucleoside use poss.
       peak plasma lev.& state of hydrat.believ.to be relat.to rapid bld.urea   milk., elderly.  risk fact.for lact.acidos., pts. with known liv.dis.risk fact., discont.
       & creatin.lev.incr., lactat.pass.in breast milk, ren. impairm., elderly,   Drug interactions: Probenecid blocks.acyclovir ren.clear.  if clinic./lab. find. suggest.lact.acidos./pronounc.hepatotoxic., pts.
       concom. nephrotox.agents incr.ren.impairm.risk., incr.neurolog.ad-  ADCO-EFAVIRENZ, AI Pharm [P/S]  at risk of ren.dysfunct./hist. hereof, concom./ recent nephrotox.
       verse event risk in elderly & ren.impairm., monit.ren.funct.& hydrat.  Efavirenz.  agents/other meds.elimin.via act. tubul.secret., monit.hepat.funct.
       lev.at high dos., underly.neurolog.abnorm./signific. hypox./ ser.hepat.  Indications: In combinat.with other antiretrovir. agents for HIV-1   for sev.mnths. aft.discont., pts.co-infect.with HIV & HBV, PrEP only
       or electrol.abnormal., TTP & haemolyt. uraem. syndr.report.with high   infect.adults, adolesc.& childr.13 kg & above and or 3 yrs and above.  in indiv. confirm.HIV-neg.immediat.bef.& at least every 3 mnths.dur.
       dos.in imunocomprom. pts., in sev.immunocomprom.pts. prolong/re-  (S4) TABS, 41/20.2.8/0929  treatm., test for hepatit.B bef. init.ther., HIV transmiss.potent./ser.
       peat.treatm.poss.results in reduc.sensit.of vir.strains which may not   709545-001: 600 mg, 30, R107,56  adverse effs. in breastfed infts., concom.didanosine, lopinavir/ rito-
       respond to cont.treatm.,      Dosage: Admin.in combinat.with a protease inhibit./ nucleoside re-  navir & discont.if advers.effs. develop, recomm.concom. atazanavir
       Interactions: Probenecid & cimetidine blocks ren.clear., concom.  vers.transcriptase inhibit. (NRTI’s). Admin.on empty stomach. Avoid   be admin. with ritonavir, act.ingred.not to be co-admin.indiv., monit.
       meds known to aff.kidn.funct. incl.ciclosporin/tacrolimus, poss. incr.   admin. with a fatty meal as absorpt. incr., consid.bedt. dos. dur.1  2-4   bone abnormalit.esp.in pts.with bone fract. hist./osteopen.risk, Ca &
                                                               st
       plasma AUC of both meds.with concom.mycophenolate mofetil.  wks ther.& in pts.exper.CNS effs.  vit.D supplementat.poss benefic., elderly, inflamm.respons.to indo-
       ADCO-ABACAVIR, AI Pharm Ltd [P/S]  Adults: Recomm.dos.: 600 mg once dly. Adolesc. & childr.17   lent/ resid. opportunist.infects.dur.init.phase of combin. anti-retrovir.
                                                                  ther.may necessit.furth.eval.& treatm., investig.poss.mitochondr.dys-
       Abacavir                      yrs.& und: 600 mg at bedt. Use only in adults & childr.weigh.great.  funct.in case of relev. S&S in any foet.expos.in utero, consid. pan-
       Indications: Antiretroviral combinat.ther.for HIV treatm.in infect.  than or equal to 40 kg  creatit. in pts.develop.abdom.pain/vomit./ elev. biochem. markers
       adults & childr.old.than 12 yrs.  (S4) CAPS, 42/20.2.8/0979, 0981,  & discont.unt.diagnos.excl., perf. CV risk assessm.in pts with evid.
       (S4) TABS, 43/20.2.8/0386.    715585-001: 50 mg, 30, R23,24  of lipodystrophy, monit. vir.load/CD4 count regular., reliable meth.
       715347-001: 300 mg, 60, R616,56  712932-001: 200 mg, 90, R207,29  of contracept.advis.
       Dosage: Do screen.for carriage of HLA-B*5701 allele bef.init./re-init.  Dosage: Admin.in combinat.with a protease inhibit./ nucleoside   Drug interactions: Ser.conc.of drugs elimin.by act. tubul.secret.
       ther. For use by physic.exper. in HIV managem.  analog. Admin.on empty stomach. Avoid admin.with a fatty meal   incr., didanosine plasma conc. incr., tenofovir conc.incr.with ataza-
                                                     st
       Adults & adolesc.over 12 yrs: Recomm.dos: 300 mg 2xdly.   as absorpt. incr., consid.bedt.dos.dur.1  2-4 wks ther. & in pts.ex-  navir, decr. lamuvidine C max  with tenofovir, incr.zidovudine C  max/AUC
       Max.600 mg dly.               per.CNS effs.                with concom.emtricitabine, decr.indinavir C max & incr.tenofovir C max ,
       (S4) ORAL SOL, 45/20.2.8/0910. 20 mg/ml  Adults: Recomm.dos.: 600 mg once dly. Adolesc. & childr.17 yrs.&   incr.abacavir C max with tenofovir, AUC & C min of atazanavir decr., incr.
       720866-001: 240 ml, R304,49   und: Admin.once dly. 13-15 kg: 200 mg. 15-20 kg: 250 mg. 20-25 kg:   tenofovir conc.with lopinavir/ritonavir, poss.incr. ser. conc.with acyclo-
       Dosage: Do screen.for carriage of HLA-B*5701 allele bef.init./re-init.  300 mg. 25-32,5 kg: 350 mg. 32,5-40 kg: 400 mg. Great.than or   vir/adefovir/dipivoxil/ cidofovir/ ganciclovir/valcyclovir/valganciclovir.
       ther. For use by physic.exper. in HIV managem.  equal to 40 kg: 600 mg.  See also MDR page 56.
       Adults & adolesc.over 12 yrs: 600 mg dly. Childr. 3 mnths-12 yrs:   Contraindications: Concom. terfenadine/ astemizole /cisapride/
       8 mg/kg 2xdly up to max. 600 mg dly.  midazolam/triazolam/ergot derivat.as ser./life threat.adverse effs.  ADCO LAMIVUDINE AND ZIDOVUDINE,
       Contraindications: Hepat.impairm., pregn.& lactat., childr.und.12 yrs.  poss., pregn. (teratogen.in anim.), breast feed not recomm., childr.  Adcock Ingram [P/S] &
       Side effects: Fatal hypersens.reacts., hypersens. sympts worsen.  und.3 yrs./weight &lt; 13 kg, concom. St John’s Wort.  Lamivudine 150 mg, zidovudine 300 mg
       with cont.ther., hypersens.reacts. are more sev.on re-challeng.incl.  Side effects: Palpitat., tachycard., tinnit., abnorm. vis., GI disturbs.,   Indications: Part of anti-retroviral combinat.ther. for treatm.of HIV
       life-threaten. hypotens. & death pres.within hrs., anaphylax., skin   malabsorpt., fatig., asthen., malaise, pain, hot flush., flu-like sympts.,   infect.adults & childr.over 12 yrs. with progress.immunodefic. , init.
       rash, erythema multiforme, Stev.-John.syndr., tox.epiderm.necroly-  hepatit., hepat.fail., allerg.reacts., redistribut./accumulat.of body fat,   prophylax.(unt. serology test results avail.) in HIV neg.adults follow.
       sis, N&V, diarrh., abdom.pain, pancreatit., elev.bld.gluc.& triglyceride   alcoh.intol., incr.appetite, arthralg./ myalg., myopathy, CNS effs., syn-  suspect./known HIV occupat.expos. Admin. of protease inhibit.
       conc., anorex., fat redistribut., lact.acidos./sev. hepatomegaly with   cope, imp.co-ordinat., convuls., migraine, paraesthes., periph. neu-  recomm.when large vol.of innoculat. occurs/when source mat.has
       steatos., headache, fatig., lethargy, fev.  ropathy, speech disords., trem., psych.disords. & aggrav.depress.,   high viral titre or when innoculat.occurs from pt.with HIV resist. to
       Special precautions: Carriage of HLA-B*5701 allele assoc.with sig-  impot., libido changes, resp. disords., skin reacts.incl.rash/erythema   zidovudine/lamivudine.
       nific.incr.hypersens.react.risk, pre-treatm.HLA-B*5701 allele screen.  multiforme & Stev.John.syndr., alopec., incr.sweat., acne, nail &   (S4) TABS, 44/20.2.8/0106
       recomm.in pts without prev.abacavir expos./bef.re-init.ther., do not   skin discolourat., rais.ser.cholester.& triglycerid. conc., weight gain/  715992-001: 60, R189,61
       use in pts.carry.HLA-B*5701 allele unless no other therapeut.option   loss, incr.tot.cholester.  Dosage: Adults & childr.over 12 yrs: 1 tab. 2xdly. Consult package
       avail., perman.discont. ther. if hypersens.react.develops & do not re-  Special precautions: Use barrier contracept.in combinat.with   insert for separ.agents admin.dur.combin.ther.
       challeng., pts.to be made aware of dangers of life threaten.hyper-  other methods, pregn.test in women of childbear.potent.bef.init.ther.,   Post expos.prophylax: Init.ther.pref.with.1-2 hrs aft. expos. Cont.
       sens.& to contact dr.immed., be aware of misdiagnos.hypersens.  poss. pass. into breast milk, must not be used as monother./ add.on   unt.confirm.of HIV status of source. Prophylact.course to be contin.
       reacts., teratogenicity shown in anim.stud., avoid in end stage ren.  as sole agent to fail.regim., consid. alternat.to clarithromycin, ref.to   for 4 wks should source be confirm.as HIV pos. Dos: 1 tab 2x dly.
       dis., consid.monit.bld.gluc. & lipids in pres.of fat re-distribut.& treat   prod.lit. when prescrib.other meds., consid.simultan. discont. of all   Dos.to be strict.adher.to. Discont.ther.as soon as source is confirm.
       lipid disords.accord., opportunist.infects.& other HIV complicat.may   antiretrovir.meds.if combinat.regim. is interrupt.because of suspect.  not to be HIV infect. If protease inhibit.reqd.follow.loc.CDC guidelines.
       still devel., advis.pt.that antiretrovir.ther.will not prev. transmiss.&   intol.& restart medicat.at same time upon resolut.of intol. sympts.,   Contraindications: Abnorm.low neutrophil counts /haemoglobin
       appropr.precaut.to contin., known risk fact.for liv.dis., suspend.ther.  intermitt.monother./sequent. reintroduct. not advis., discont.in sev.  lev., childr.bel.12 yrs., concom. stavudine/zalcitabine
       in clinic.find.suggest. of lact.acidos./hepatotox., immune reconstit.  rash & consid.prophylax. with appropr.anthistam./corticoster.for   Side effects: Freq: Hyperlactat., headache, dizzin., cough, nas.
       syndr. report.dur.init.treatm.with combinat.antiretrov. ther. in sev.im-  mild to mod. rash to improv.tol.& resolv.rash, prev.ment. illn./subst.  sympts., naus., vomit., abdom.pain/cramps, diarrh., skin reacts.,
       mune defic., osteonecros.with advanc. HIV dis./long term expos.to   abuse, be alert to psychos.-like reacts.& sev.ac.depress.reports, liv.  alopec., arthralg, musculoskelet.pain, malaise, fatig., fev., myalg.,
       combinat.ARV ther., hered.fruct.intol.,   dis., monit.liv.enzymes partic.in known/suspect.hepatit.B/C infect.  anaem., neutropen., leucopen., liv. enzym./bilirub.incr. Less freq:
       Drug interactions: Alcoh.decr.eliminat., syst. methadone clear.incr.  hist./ concom.liv.tox.assoc.meds., cholestr.monit.  Bld.dyscras., lact. acidos. & sev.hepatomegaly with steatos. som-</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page297.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page293.html">293</a>&nbsp;&nbsp;&nbsp;<a href="page294.html">294</a>&nbsp;&nbsp;&nbsp;<a href="page295.html">295</a>&nbsp;&nbsp;&nbsp;<a href="page296.html">296</a>&nbsp;&nbsp;&nbsp;<a href="page297.html">297</a>&nbsp;&nbsp;&nbsp;<a href="page298.html">298</a>&nbsp;&nbsp;&nbsp;<a href="page299.html">299</a>&nbsp;&nbsp;&nbsp;<a href="page300.html">300</a>&nbsp;&nbsp;&nbsp;<a href="page301.html">301</a>&nbsp;&nbsp;&nbsp;<a href="page302.html">302</a>&nbsp;&nbsp;&nbsp;<a href="page303.html">303</a>
             </td>
             <td width="35%"><a href="page299.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page299.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
